Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pepsin is a major aspartic protease (EC 3.4.23.1) produced in the stomach that facilitates the digestion of dietary proteins by cleaving peptide bonds (StatPearls, 2023). It is secreted as the inactive zymogen pepsinogen by gastric chief cells and is activated by the low pH environment created by hydrochloric acid (HCl) (PubMed, PMID: 25102588). Gastric luminal irritants, which include pepsin, HCl, and refluxed bile acids, are collectively known as aggressive factors that can damage the gastrointestinal mucosa if the protective mucus-bicarbonate barrier is compromised (NCBI, NBK537005). This damage is a primary driver of conditions such as peptic ulcer disease and gastroesophageal reflux disease (GERD). Pharmacological intervention focuses on neutralizing these irritants using antacids, inhibiting pepsin activity through pH elevation, or providing a physical barrier with mucosal protectants like sucralfate and alginates to prevent tissue injury (DrugBank, DB00364; PubMed, PMID: 17269992).
Neutralization of gastric acid, physical sequestration of pepsin and bile acids, and formation of a protective barrier over damaged mucosa.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pepsin and gastric luminal irritants.